Following compliance with the listing criteria, Nuwellis Inc. (NASDAQ: NUWE) shares were up 21.05% to trade at $11.10 at the time of the most recent check.
When did NUWE receive the certification?
On Tuesday, Nuwellis (NUWE) said that on December 27, 2022, the company had received official notification from The Nasdaq Stock Market LLC’s Listing Qualifications Staff. According to the notification, Nuwellis has fully demonstrated compliance with the Nasdaq Listing Rules’ minimum bid price criterion.
The notification said that the Company has restored compliance with Nasdaq Listing Rule 5550(a)(2) as a consequence of the closing bid price of NUWE’s common stock being at a minimum of $1.00 per share for a minimum of 10 straight business days, and it advised that the matter is now closed.
NUWE announced peer-reviewed publication:
The results of a 10-year, real-world retrospective investigation of 334 hospitalized patients with acute decompensated heart failure and fluid overload administered with variable ultrafiltration (UF) utilizing the Aquadex FlexFlow System were published in peer-reviewed journals this month, according to NUWE.
The analysis carried out by researchers at Abington Hospital-Jefferson Health in Abington, Pennsylvania, and published in the American Heart Journal Plus showed significant decreases in cardiovascular disease hospital admissions and 30-day hospital rehospitalization, as well as improvements in renal function response, when using Aquadex ultrafiltration.
The published study, “Ten-Year Real-World Experience with Ultrafiltration for the Management of Acute Decompensated Heart Failure,” found that patients’ hospitalizations for heart failure decreased by 81% overall each year, 55% of patients successfully lost more than 15 pounds over time, and patients who received UF with Aquadex experienced rehospitalizations that were 48% lower than the national average at 30 days (12.4% vs. 24%).
According to the review, patients who are hospitalized with decompensated heart failure can remove a large amount of volume safely and successfully with ultrafiltration. This real-world data shows that ultrafiltration compares positively for weight/volume drop and renal function response compared to prior studies, and this may be related to a decreased likelihood of heart failure re-hospitalization.
How did NUWE continue to do well?
The findings of NUWE are in line with the AVOID-HF Win Ratio analysis, which was awhile back displayed at the Heart Failure Society of America (HFSA) 2022 Annual Scientific Meeting and showed that ultrafiltration therapy using the Aquadex System is statistically superior clinically to diuretics in reducing heart failure events within 30 and 90 days. Aquadex treatment will become the norm for medication adherence in cardiovascular disease patients who do not respond to diuretics, according to Nuwellis (NUWE).